Development and Validation of Overall Survival and Amputation-Free Survival Prediction Models for Patients with Peripheral Arterial Disease Who underwent Endovascular Therapy

被引:0
作者
Shi, Meihong [1 ,2 ,3 ]
Jian, Liping [1 ]
Liu, Xiaoyu [1 ]
Liu, Feng [3 ]
Liu, Yang [4 ]
Yang, Xi [3 ]
Liu, Xinjun [4 ]
Xiong, Huarong [3 ]
Wang, Dan [3 ]
Song, Pan [1 ]
Quan, Xiaoyan [1 ]
Chen, Qin [1 ,3 ]
Hu, Xiuying [2 ]
Cui, Chi [3 ,5 ]
机构
[1] Southwest Med Univ, Sch Nursing, Luzhou, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Innovat Ctr Nursing Res, Nursing Key Lab Sichuan Prov, Chengdu, Sichuan, Peoples R China
[3] Southwest Med Univ, Affiliated Hosp, Luzhou, Sichuan, Peoples R China
[4] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China
[5] Chongqing Med Univ, Southwest Jiaotong Univ, Affiliated Hosp, Ctr Vasc & Intervent Surg,Affiliated Hosp Chengdu, Chengdu, Sichuan, Peoples R China
关键词
survival; amputation-free survival; peripheral arterial disease; endovascular therapy; prediction model; nomogram; CRITICAL LIMB ISCHEMIA; MEDICAL-MANAGEMENT; RISK-FACTORS; MORTALITY; OUTCOMES; CILOSTAZOL; SOCIETY; PREVENTION; GUIDELINES; FRAILTY;
D O I
10.1177/15266028251328474
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: To identify the most valuable predictor associated with overall survival (OS) and amputation-free survival (AFS) and to develop and validate OS and AFS prediction models for patients with peripheral arterial disease (PAD) who underwent endovascular therapy (EVT). Methods: This study included patient with PAD who EVT between January 2018 to June 2023 across 3 hospitals in southwest China. Outcomes were OS and AFS at 1, 2, and 3 years. Results: A total of 2792 consecutive patients with PAD who underwent EVT were included, with an average follow-up period was 14.0 +/- 8.7 months. During the follow-up period, 412 (14.8%) patients died, and 737 (26.4%) patients experienced either amputation or death. The OS rates in 1-, 2-, and 3-years were 89.3%, 81.2%, and 74.2% in the whole cohort, respectively. In terms of AFS, the rates at 1-, 2-, and 3-years were 81.7%, 68.3%, and 54.1%, respectively. Predictors in the OS prediction model included age, diabetes mellitus (DM), body mass index (BMI) classification, dialysis-dependent renal failure (DRF), Rutherford classification, antiplatelet therapy, and cilostazol therapy (p < 0.05). Predictors in the AFS prediction model included DM, chronic obstructive pulmonary disease, DRF Rutherford classification, antiplatelet therapy, and cilostazol therapy (p < 0.05). The area under the curve and calibration curves for training, internal, and external validation of both OS and AFS prediction models indicated good performance. Conclusions: This study demonstrates that both OS and AFS prediction models exhibit good discriminative ability to predict survival rate and AFS rate in patients with PAD. PAD patients with DM, DRF, Rutherford classification R5 and R6, absence of antiplatelet, and cilostazol therapy were associated with significantly lower OS and AFS rates. Controlling these risk predictors may be guide patient care in clinical settings.
引用
收藏
页数:17
相关论文
共 76 条
[1]   2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) [J].
Aboyans, Victor ;
Ricco, Jean-Baptiste ;
Bartelink, Marie-Louise E. L. ;
Bjorck, Martin ;
Brodmann, Marianne ;
Cohnert, Tina ;
Collet, Jean-Philippe ;
Czerny, Martin ;
De Carlo, Marco ;
Debus, Sebastian ;
Espinola-Klein, Christine ;
Kahan, Thomas ;
Kownator, Serge ;
Mazzolai, Lucia ;
Naylor, A. Ross ;
Roffi, Marco ;
Roether, Joachim ;
Sprynger, Muriel ;
Tendera, Michal ;
Tepe, Gunnar ;
Venermo, Maarit ;
Vlachopoulos, Charalambos ;
Desormais, Ileana .
EUROPEAN HEART JOURNAL, 2018, 39 (09) :763-+
[2]  
Aitken SJ, 2020, AUST J GEN PRACT, V49, P239, DOI 10.31128/AJGP-11-19-5160
[3]   The Use and Impact of Cilostazol on Patients Undergoing Endovascular Peripheral Interventions [J].
Alameddine, Dana ;
Damara, Fachreza Aryo ;
Rodriguez, Paula Pinto ;
Huttler, Joshua ;
Slade, Martin D. ;
Arhuidese, Isibor ;
Aboian, Edouard ;
Chaar, Cassius Iyad Ochoa .
ANNALS OF VASCULAR SURGERY, 2024, 103 :47-57
[4]   Modified Frailty Index Can Be Used to Predict Adverse Outcomes and Mortality after Lower Extremity Bypass Surgery [J].
Ali, Tarik Z. ;
Lehman, Erik B. ;
Aziz, Faisal .
ANNALS OF VASCULAR SURGERY, 2018, 46 :168-177
[5]   Risk Factors for Mortality Among Individuals With Peripheral Arterial Disease [J].
Amrock, Stephen M. ;
Abraham, Cherrie Z. ;
Jung, Enjae ;
Morris, Pamela B. ;
Shapiro, Michael D. .
AMERICAN JOURNAL OF CARDIOLOGY, 2017, 120 (05) :862-867
[6]  
Cosentino Francesco, 2020, Eur Heart J, V41, P255, DOI [10.1093/eurheartj/ehz828, 10.1093/eurheartj/ehz486]
[7]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[8]   Critical Limb Ischemia and Intermediate-Term Survival [J].
Beckman, Joshua A. ;
Creager, Mark A. .
JACC-CARDIOVASCULAR INTERVENTIONS, 2014, 7 (12) :1450-1452
[9]   Cilostazol for intermittent claudication [J].
Bedenis, Rachel ;
Stewart, Marlene ;
Cleanthis, Marcus ;
Robless, Peter ;
Mikhailidis, Dimitri P. ;
Stansby, Gerard .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (10)
[10]   Evidence-Based Medical Management of Peripheral Artery Disease [J].
Bevan, Graham H. ;
Solaru, Khendi T. White .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2020, 40 (03) :541-553